CVE shorts build into earnings, but the ATH deal remains the real catalyst

CVE arrives at its October 29 Q3 results with the short interest story having shifted meaningfully since the last note, though the Athabasca Oil deal mechanics continue to set the broader context.

Short interest has climbed sharply over the past month, a move worth flagging even at still-low absolute levels. Shares short rose 14.2% on the week and 37.9% over the past month, reaching 17.5 million shares, equivalent to 0.93% of the free float. A week ago this note described positioning as inert. That has changed. The jump from roughly 10.2 million shares in early October to 15.4 million around mid-month, and then to 17.5 million, traces a clear step-change pattern in the days immediately before and around the earnings date. Borrow costs have followed, rising 31.5% on the week to 0.70%, though they remain low in absolute terms. Availability is still extraordinarily loose at 5,484%, so there is no mechanical pressure on short sellers, and the borrow market offers no friction. The short score has edged to 28.9, the highest reading in the ten-day history shown, but the level itself remains modest. The picture here is one of rising caution into the print rather than a crowded short.

The corporate action story remains the more structural angle. The agreed takeover of Athabasca Oil Corporation continues to work through index mechanics. ORTEX puts the probability of a TSX 60 share-count increase at 90%, with an estimated $34M of forced index-tracker buying expected around December 14 to 18, roughly 0.2 days of normal volume. The MSCI World and FTSE All-World reviews each carry 65% probability, with $71M and $41M of estimated buying respectively. These remain forecasts rather than confirmed announcements, and dates are estimated.

The analyst data on file is too old to carry into this note, predating 2021, so the Street view is not quoted here. On valuation, the trailing P/E has compressed to 9.2 times, down 2.3 points over the past 30 days, while EV/EBITDA has fallen to 5.2 times, also lower on the month. The earnings yield factor ranks in the 66th percentile. EPS momentum is the standout, ranking in the 94th percentile on a 30-day basis and the 84th on 90 days. That is the clearest signal that the estimate revision cycle has been running in CVE's favour in the lead-up to the print.

On the institutional register, Capital Research and Management held 10.1% as of September 30, adding roughly 5.6 million shares in the period. BMO Asset Management and T. Rowe Price also added material positions in the September quarter, 9.5 million and 7.1 million shares respectively. CK Hutchison Holdings sits at 16.7% with no reported change since August 2025. Two Capital Group entities, Capital World Investors and Capital Research Global Investors, both filed Schedule 13G amendments showing reduced stakes falling below the 5% disclosure threshold, from 6.1% to 4.2% and from 5.9% to 3.2% respectively. As the filing disclosure notes, positions are as last disclosed and holders dropping below 5% may not file again.

Peer performance on the week is mixed. CNQ rose 1.3% and SU gained 0.8%, while CVE fell 1.5% over the same period. VET was the week's standout in the group, up 4.3%. CVE underperformed the immediate peer set even as Canadian energy names broadly held up, suggesting some stock-specific caution ahead of Wednesday's results.

The earnings history is limited but directional: the most recent Q2 print in late July produced a next-day move of 8.8%, with a partial give-back over the following five days. The Q3 print on October 29 is therefore the next event at which the short build will be tested, with the ATH deal mechanics providing a separate, slower-moving layer underneath.